TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06979453: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderat

Sponsor: Bristol-Myers Squibb · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 366 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$439,632

Rescue Site Savings

+$293,088

Unlock Full NCT06979453 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06979453 Rescue Dossier →